


Supplementary Figure 1



Supplementary Figure 1 Afatinib is more effective than erlotinib at impairing mTORC1 activation in lung adenocarcinoma patients harboring EGFR mutation.

(a) and **(b)** Immunohistochemical analysis of nine lung cancer patients. Representative immunohistochemical staining of p-T389-S6K1, S6K1, p-S473-AKT, and AKT using lung cancer tissues from the patients receiving neoadjuvant erlotinib **(a)** or afatinib **(b)**.